STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,512,492)	$ (34,692,210)	$ (27,352,679)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	663,988	720,494	745,496
Issuance of common stock and options for services - non-employees	751,651	565,915	694,955
Modification of warrants issued to consultants	0	0	76,991
Equity based compensation	2,113,433	5,105,827	3,958,637
Common stock contributed to 401(k) plan	161,571	165,646	155,434
Impairment loss on abandonment of patents	0	0	1,182
Loss on retired equipment	248	313	268
Gain on derivative instruments	(14,013,726)	(282,616)	(248,767)
Loss on debt extinguishment	0	620,457	0
Capitalized lease interest	227,773	249,493	241,829
(Increase)/decrease in assets:
Receivables	(1,960)	(5,394)	(7,557)
Prepaid expenses	15,999	(68,268)	(158,088)
Inventory used for R&D and manufacturing	393,197	50,181	(435,392)
Deposits	145,005	150,000	(200,000)
Increase/(decrease) in liabilities:
Accounts payable	(2,389,931)	3,981,886	(751,971)
Accrued expenses	290,097	(458,633)	433,712
Deferred revenue	(1,639)	48	46
Due to employees	72,397	57,170	(78,376)
Deferred rent liability	1,896	6,358	(3,739)
Net cash used in operating activities	(23,082,493)	(23,833,333)	(22,928,019)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(31,405)	(73,399)	(103,977)
Expenditures for patent costs	(2,819)	(20,132)	(34,887)
Net cash used in investing activities	(34,224)	(93,531)	(138,864)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	21,420,301	21,148,378	28,428,641
Payment on related party loan	(1,104,057)
Proceeds from exercise of warrants	0	0	3,118,387
Payments on obligations under capital lease	(8,213)	(8,452)	(8,137)
Net cash provided by financing activities	20,308,031	21,139,926	31,538,891
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(2,808,686)	(2,786,938)	8,472,008
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	5,726,682	8,513,620	41,612
CASH AND CASH EQUIVALENTS, END OF YEAR	2,917,996	5,726,682	8,513,620
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services	305,341	0	0
Research and office equipment included in accounts payable at year end	0	(2,345)	(1,074)
Capitalizable patent costs included in accounts payable at year end	0	(11,685)	4,474
Patent costs purchased with common stock	0	0	9,999
Lease payments included in accounts payable at year end	815	43	3,477
Fair value of warrant liabilities on the date of issuance reclassed to liabilities	(8,722,073)	(8,463,957)	(5,320,989)
Financing costs included in accounts payable at year end	46,605	0	0
Forfeiture of unvested restricted stock	0	1,000	0
Stock issued under an anti-dilution provision and cashless exercise of warrants	0	0	(16,375)
Prepaid amount under consulting services paid with issuance of common stock	18,021	3,861	31,085
Cash paid for interest expense	$ 1,900,567	$ 1,969,499	$ 1,965,949